文献速递核素与放射性配体治疗肿瘤 PET/CT

[68Ga]Ga-PSMA-11 PET预测[177Lu]Lu-PSMA-617治疗中危及器官和小病灶的吸收剂量

[68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-10-08

该研究纳入10例低瘤负荷激素敏感性前列腺癌患者,在[177Lu]Lu-PSMA-617治疗前进行[68Ga]Ga-PSMA-11 PET/CT,治疗中采集SPECT/CT,按MIRD方案计算吸收剂量并比较预测值与实际值。结果显示PET可较好预测肾脏、肝脏和唾液腺的吸收剂量,对病灶的预测能力有限。

要点

  • 单时间点[68Ga]Ga-PSMA PET可预测[177Lu]Lu-PSMA治疗对危及器官的吸收剂量。
  • PET对病灶吸收剂量的预测能力有限,患者间动力学差异大。
  • 该策略有助于治疗管理和个体化[177Lu]Lu-PSMA治疗。

核心结论

  • 单时间点[68Ga]Ga-PSMA PET扫描可用于预测[177Lu]Lu-PSMA治疗对器官的吸收剂量,对病灶的预测能力有限。

研究设计与样本

  • 研究纳入10例低瘤负荷激素敏感性前列腺癌患者,治疗前接受[68Ga]Ga-PSMA-11 PET/CT,随后接受3 GBq [177Lu]Lu-PSMA-617治疗。
  • 治疗中在1、24、48、72和168小时采集SPECT/CT,按MIRD方案计算器官和病灶(n=22)的吸收剂量。
  • 基于[68Ga]Ga-PSMA-PET/CT的预测使用注射后1小时的示踪剂摄取和SPECT的平均组织有效半衰期。

主要发现

  • 肾脏(使用2.2缩放因子)的PET/SPECT吸收剂量比为1.01 ± 0.21。
  • 肝脏的PET/SPECT吸收剂量比为1.10 ± 0.15。
  • 下颌下腺的PET/SPECT吸收剂量比为1.20 ± 0.34。
  • 腮腺的PET/SPECT吸收剂量比为1.11 ± 0.29。
  • 病灶的PET/SPECT吸收剂量比为1.3 ± 0.7(范围0.4-2.7,相关系数r=0.69,p<0.01),患者间动力学差异大。

临床怎么用

  • 可利用治疗前[68Ga]Ga-PSMA PET/CT预测[177Lu]Lu-PSMA治疗对肾脏、肝脏和唾液腺的吸收剂量,辅助治疗管理。
  • 对病灶吸收剂量的预测需谨慎,因患者间动力学差异大且预测能力有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patient eligibility for [177Lu]Lu-PSMA therapy remains a challenge, with only 40-60% response rate when patient selection is done based on the lesion uptake (SUV) on [68Ga]Ga-PSMA-PET/CT. Prediction of absorbed dose based on this pre-treatment scan could improve patient selection and help to individualize treatment by maximizing the absorbed dose to target lesions while adhering to the threshold doses for the organs at risk (kidneys, salivary glands, and liver). METHODS: Ten patients with low-volume hormone-sensitive prostate cancer received a pre-therapeutic [68Ga]Ga-PSMA-11 PET/CT, followed by 3 GBq [177Lu]Lu-PSMA-617 therapy. Intra-therapeutically, SPECT/CT was acquired at 1, 24, 48, 72, and 168 h. Absorbed dose in organs and lesions (n = 22) was determined according to the MIRD scheme. Absorbed dose prediction based on [68Ga]Ga-PSMA-PET/CT was performed using tracer uptake at 1 h post-injection and the mean tissue effective half-life on SPECT. Predicted PET/actual SPECT absorbed dose ratios were determined for each target volume. RESULTS: PET/SPECT absorbed dose ratio was 1.01 ± 0.21, 1.10 ± 0.15, 1.20 ± 0.34, and 1.11 ± 0.29 for kidneys (using a 2.2 scaling factor), liver, submandibular, and parotid glands, respectively. While a large inter-patient variation in lesion kinetics was observed, PET/SPECT absorbed dose ratio was 1.3 ± 0.7 (range: 0.4-2.7, correlation coefficient r = 0.69, p < 0.01). CONCLUSION: A single time point [68Ga]Ga-PSMA-PET scan can be used to predict the absorbed dose of [177Lu]Lu-PSMA therapy to organs, and (to a limited extent) to lesions. This strategy facilitates in treatment management and could increase the personalization of [177Lu]Lu-PSMA therapy.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Peters SMB, Hofferber R, Privé BM, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nucl Med Mol Imaging. 2021. PMID: 34623453. doi:10.1007/s00259-021-05538-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。